

DOCKET NO.: JANS-0071/JAB-1690

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Jose Ingacio Andres-gil, et al.

Confirmation No.: **6227**

Application No.: **10/510,220**

Group Art Unit: **1624**

Filing Date: **October 1, 2004**

Examiner: **Emily B. Bernhardt**

For: **Substituted Amino Isoxazoline Derivatives And Their Use As Anti-Depressants**


REQUEST FOR CORRECTED FILING RECEIPT

1. Attached is a copy of the Official Filing Receipt received from the PTO in the above application for which issuance of a Corrected Filing Receipt is respectfully requested. The requested changes are noted thereon, as well as listed below.
2. There is an error with respect to the following data which is:
☒ omitted. The specification was updated to include the foreign priority in a Preliminary Amendment dated October 1, 2004.

Error in	Correct data
1. Applicant's name	1.
2. Applicant's address	2.
3. Title	3.
4. Filing Date	4.
5. Application Number	5.
6. Foreign/PCT Application Re:	6. EP 02076239.9 April 2, 2002
7. Other:	7.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050.

Date: **3/13/07**


Stephanie A. Barbosa, Ph.D.
Registration No. 51,430

Woodcock Washburn LLP
Cira Centre
2929 Arch Street, 12th Floor
Philadelphia, PA 19104-2891
Telephone: (215) 568-3100
Facsimile: (215) 568-3439



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/510,220	10/01/2004	1615	950	JAB-1690		14	2

27777

PHILIP S. JOHNSON
 JOHNSON & JOHNSON
 ONE JOHNSON & JOHNSON PLAZA
 NEW BRUNSWICK, NJ 08933-7003

RECEIVED

MAY 27 2005

J&J PAT. DKT. SECTION

CONFIRMATION NO. 6227

FILING RECEIPT



OC000000016062106

Date Mailed: 05/20/2005

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Jose Ignacio Andres-Gil, Madrid, SPAIN;
 Manuel Jesus Alcazar-Vaca, Toledo, SPAIN;
 Margaretha Henrica Maria Bakker, Alsbach-Haehnlein, GERMANY;
 Ana, Isabel De Lucas Olivares, Toledo, SPAIN;

Power of Attorney: The patent practitioners associated with Customer Number 27777.

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/EP03/03245 03/27/2003

Foreign Applications

EP 02076239.9 04/02/2002

Projected Publication Date: 08/25/2005

Non-Publication Request: No

Early Publication Request: No

Title

Substituted amino isoxazoline derivatives and their use as anti-depressants

*Please correct:
 updated in Pre
 Amendment
 October 1, 2004*

Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).